Alprostadil (Caverject / MUSE) Side Effects: Potentially Permanent Adverse Events Explained

What Permanent or Long-Lasting Side Effects Can Alprostadil Cause?

Alprostadil causes permanent harm through two main pathways: repeated mechanical and chemical trauma to corporal or urethral tissue, and ischemia from blood flow that cannot resolve on its own. The injuries that follow those pathways, fibrosis, plaque formation, urethral stricture, and erectile dysfunction worsened beyond the baseline, can outlast the drug by years or decades.

The FDA-approved prescribing information for Caverject lists fibrosis of the penis, including Peyronie's disease, as an adverse reaction observed in approximately 3% of patients in long-term studies. [1] Post-market experience and urology case series suggest the rate climbs with injection frequency, needle gauge, and injection technique errors.

The Four Harms Most Likely to Become Permanent

Clinicians generally group alprostadil's durable harms into four categories:

1. Corporal fibrosis, replacement of erectile smooth muscle with scar tissue, reducing rigidity and penile length.
2. Peyronie's-like plaques, discrete fibrous nodules that cause penile curvature and painful erections.
3. Ischemic priapism sequelae, vascular and smooth-muscle necrosis when an erection exceeds 4 to 6 hours without treatment.
4. Urethral scarring and stricture, specific to MUSE and to injections that miss the corpus cavernosum.

Each is discussed in detail below.

Penile Fibrosis: The Most Common Permanent Risk

Penile fibrosis is the most frequently documented permanent complication of long-term intracavernosal alprostadil. Repeated needle trauma combined with the drug's local prostaglandin activity triggers a chronic inflammatory response inside the corpus cavernosum. Over months to years, that inflammation is replaced by collagen deposition, stiffening the erectile tissue and reducing its capacity to expand.

What the Prescribing Label and Trials Report

The Caverject package insert states that fibrosis was reported in 3% of patients across controlled and uncontrolled studies involving more than 1,800 men. [1] A 1996 phase-III trial published in the New England Journal of Medicine (N=296, 6-month follow-up) reported a 2% incidence of fibrosis-related findings in the alprostadil arm versus none in placebo. [2] Longer follow-up data from open-label extensions pushed that figure toward 7 to 8% at 18 months of twice-weekly use, aligning with real-world urology clinic observations.

How Fibrosis Affects Sexual Function Permanently

Once fibrotic scarring replaces more than roughly 20 to 30% of smooth-muscle area, the corpus cavernosum loses the compliance needed for a rigid erection. Ultrasound and MRI studies show that even after alprostadil is discontinued, established fibrosis does not reliably regress. Clinicians at major academic centers have reported that men with moderate-to-severe fibrosis often require penile prosthesis implantation to recover functional erections, a surgical escalation that would otherwise have been years away.

Reducing Fibrosis Risk Without Stopping Treatment

The American Urological Association (AUA) 2018 erectile dysfunction guideline recommends the lowest effective dose, the smallest appropriate needle gauge (27 to 30 gauge), strict sterile technique, and rotation of injection sites to the lateral midshaft to reduce cumulative trauma. [3] Resting injections for 24 hours between doses and limiting use to no more than three times per week are practical steps that slow, but do not eliminate, cumulative tissue injury.

Peyronie's Disease and Plaque Formation

Alprostadil does not cause classic Peyronie's disease, which is a connective-tissue disorder with a distinct genetic component. However, repeated intracavernosal injections can produce Peyronie's-like fibrotic plaques that are clinically indistinguishable on examination and ultrasound. The shared endpoint is penile curvature, painful erections, and eventual shortening.

How Injections Trigger Plaques

Each injection creates a micro-hematoma at the needle entry site. In most men, that small bleed resolves without consequence. In a subset, likely those with subclinical connective-tissue susceptibility or poor injection technique, organized collagen replaces the hematoma, forming a palpable nodule on the tunica albuginea. [4]

The FDA's Adverse Event Reporting System (FAERS) contains dozens of post-market reports of Peyronie's-like plaques attributed to Caverject. Because FAERS data are voluntarily submitted and not population-denominator-corrected, the absolute rate is difficult to extract; however, the signal has been present in the database continuously since 1995 and was substantial enough to warrant inclusion in the Caverject label. [1]

Prognosis for Plaques After Stopping Alprostadil

Injection-related plaques are more likely to stabilize after stopping alprostadil than to regress fully. A 2020 retrospective study in The Journal of Sexual Medicine (N=87 men with injection-related fibrosis) found that 61% had stable plaque size at 12-month follow-up after discontinuation, while 22% showed partial regression and 17% showed continued growth despite no ongoing injections, suggesting that the inflammatory cascade can persist after the chemical stimulus is removed. [5]

Treatment options for established plaques include oral pentoxifylline, intralesional collagenase clostridium histolyticum (Xiaflex), and surgical correction for curvature exceeding 30 degrees, none of which reliably restore the pre-injury anatomy.

Priapism and Ischemic Injury: A Time-Sensitive Emergency

Priapism, an erection lasting more than 4 hours not associated with sexual stimulation, is the alprostadil complication with the most compressed timeline for permanent harm. Ischemic (low-flow) priapism is a compartment syndrome of the penis. Without drainage and pharmacologic reversal, the oxygen debt inside the corpus cavernosum causes smooth-muscle necrosis beginning at approximately 4 to 6 hours and progresses to irreversible fibrosis within 12 to 24 hours. [6]

Incidence and Risk Factors

The Caverject label cites a priapism rate of approximately 1% in clinical trials, though this figure varies by dose, baseline vasomotor tone, and concomitant medications. [1] Men taking phosphodiesterase-5 inhibitors alongside alprostadil, or those on anticoagulants and vasoactive antihypertensives, carry a meaningfully higher risk.

A 2017 analysis of emergency department visits in the United States estimated that alprostadil accounts for roughly 20% of drug-induced priapism presentations, second only to antipsychotics as a pharmacologic cause. [7]

The 4-Hour Rule

The AUA and the European Association of Urology both state that ischemic priapism lasting more than 4 hours requires emergency urological management, typically aspiration and intracavernosal injection of a sympathomimetic agent such as phenylephrine 100 to 500 mcg. [3] Men prescribed Caverject should receive explicit written instructions to present to an emergency department if an erection has not resolved within 4 hours, not 6 hours, not "in the morning."

Permanent Consequences of Untreated Priapism

A prospective study following 42 men with ischemic priapism lasting more than 24 hours found that 90% developed clinically significant erectile dysfunction within 6 months, and more than half had MRI-confirmed corporal fibrosis at 12 months. [8] These men did not simply return to their pre-priapism baseline after the event resolved. The priapism itself inflicted the permanent injury.

HealthRX Priapism Response Framework for Caverject Users

Clinicians at HealthRX use the following threshold-based protocol for patient counseling at prescription initiation:

• 0 to 2 hours: Monitor at home. Normal variation in resolution time.
• 2 to 3 hours: Use any prescribed detumescence instructions (e.g., cold compress, light exercise). Contact the prescribing provider.
• 3 to 4 hours: Proceed to the nearest emergency department immediately. Do not wait.
• After 4 hours: Declare a urological emergency. Aspiration and phenylephrine are first-line; surgical shunting may be required.

This framework is intended to close the gap between drug dispensing and patient awareness, since delayed presentation is the primary modifiable risk factor for permanent ischemic injury.

Urethral Scarring and Stricture: The MUSE-Specific Risk

MUSE (medicated urethral system for erection) delivers a 125 mcg to 1,000 mcg alprostadil pellet into the urethra via a small applicator. The localized chemical exposure and mechanical insertion create a different injury pattern than intracavernosal injection.

Reported Urethral Adverse Events

The MUSE prescribing information lists urethral burning and minor urethral bleeding as common adverse effects. [9] Less common but potentially permanent is urethral fibrosis with progressive stricture formation, a narrowing that restricts urine flow and may require urethroscopic dilation or urethroplasty.

Case reports in the urological literature describe men with urethral strictures after 12 to 36 months of regular MUSE use, with strictures located at or just proximal to the external urethral meatus, the region of highest pellet contact. The incidence is not precisely quantifiable from trial data because the key MUSE trials (N=1,511 men, 12-week primary endpoint) were not powered or structured to capture long-term urethral anatomy changes. [10]

Female Partner Exposure

MUSE transfers alprostadil to the vaginal mucosa during intercourse. The label recommends a condom barrier for this reason. Women who are pregnant or who may become pregnant should not be exposed to alprostadil because of potential effects on fetal circulation through prostaglandin activity. [9] This is not a permanent risk to the male user, but it is an often-overlooked safety point that affects partner management.

Hypotension and Cardiovascular Events: Rare but Serious

Alprostadil is a systemic vasodilator when absorbed beyond the local site. MUSE carries higher systemic absorption than intracavernosal injection, making symptomatic hypotension more common with the suppository formulation, reported in approximately 3% of MUSE users in the key trial, compared with less than 1% for Caverject. [9][10]

Who Is at Highest Risk

Men with baseline orthostatic hypotension, those taking alpha-blockers (e.g., tamsulosin for benign prostatic hyperplasia), and men on nitrates carry the highest risk of clinically significant blood-pressure drops. A fall resulting from hypotension can cause permanent orthopedic injury independent of the drug's direct pharmacologic actions on penile tissue.

Syncope-related falls have appeared in FAERS reports for MUSE. The label advises that the first dose of MUSE should be administered in a physician's office where blood pressure can be monitored. [9]

Infection and Penile Abscess: A Low-Frequency Permanent Risk

Injection-site infection is uncommon with proper sterile technique, the key Caverject trials reported infection rates below 1%. However, when infection does develop in the corpus cavernosum, the consequences can be permanent. Corporal abscess, if not drained and treated early with intravenous antibiotics, can destroy erectile tissue, seed a penile prosthesis if one is later implanted, or require surgical debridement that removes functioning tissue.

The FDA label notes that alprostadil should not be used in men with penile implants or with conditions predisposing to infection. [1] Immunocompromised men, including those with poorly controlled diabetes, HIV, or chronic steroid use, face an amplified risk that warrants explicit counseling before initiation.

Hormone and Systemic Effects: What Long-Term Data Show

Because intracavernosal alprostadil acts primarily locally, systemic hormonal disruption is not an established permanent effect. Plasma alprostadil concentrations after intracavernosal injection of 20 mcg are detectable only transiently and fall below the assay limit of quantification within 60 minutes in most pharmacokinetic studies. [1]

Repeated prostaglandin E1 exposure does not suppress the hypothalamic-pituitary-gonadal axis or alter serum testosterone in published studies, a common patient concern that can be addressed directly and reassuringly in the clinical encounter.

Monitoring Schedule to Detect Permanent Injury Early

Early detection is the only evidence-supported strategy for preventing progression of fibrosis, plaques, and urethral changes into fixed structural deformity. The following monitoring intervals are consistent with AUA guidance and HealthRX clinical protocols:

• Baseline: Physical examination of the penis, including palpation for plaques; Peyronie's Disease Questionnaire or equivalent patient-reported outcome measure; and, where available, penile duplex Doppler ultrasound to document baseline blood flow.
• 3 months: Telephone or telehealth check-in focused on pain, curvature, nodules, and injection technique review.
• 6 months: In-person or video examination; repeat palpation; dose adjustment if fibrosis is suspected.
• 12 months and annually thereafter: Full examination including duplex Doppler if curvature or palpable nodules are present.

Discontinuation of alprostadil should be recommended promptly when a palpable plaque is found, when penile curvature exceeds 15 to 20 degrees from baseline, or when ultrasound confirms new areas of fibrosis. Continuing injections through evolving fibrosis accelerates the injury.

Drug Interactions That Amplify Permanent Harm

Several drug-drug interactions raise the baseline risk of permanent alprostadil-related injury:

• PDE-5 inhibitors (sildenafil, tadalafil, vardenafil): Additive vasodilation increases priapism risk. Combination use is off-label and should be approached with extreme caution, if at all.
• Anticoagulants (warfarin, apixaban, rivaroxaban): Amplify injection-site hematoma formation, increasing fibrosis risk.
• Alpha-blockers (tamsulosin, alfuzosin): Potentiate systemic hypotension, especially with MUSE.
• Antipsychotics with alpha-blocking activity (chlorpromazine, thioridazine): Raise baseline priapism risk independently; combination with alprostadil may increase that risk additively.

Prescribers should conduct a full medication reconciliation before initiating either Caverject or MUSE. A single missed interaction review can convert a manageable adverse event into an irreversible one.

Rare Side Effects of Alprostadil: A Complete Summary

Because the FAQ below addresses specific rare side effects, a consolidated table is useful here.

| Side Effect | Estimated Frequency | Permanent Potential | |---|---|---| | Penile fibrosis | 3 to 8% (long-term injection) | Yes, if severe | | Peyronie's-like plaque | ~2 to 3% (chronic use) | Yes, partial regression possible | | Ischemic priapism | ~1% per episode | Yes, if untreated past 4 to 6 hours | | Urethral stricture (MUSE) | Rare; not precisely quantified | Yes | | Penile abscess | <1% | Yes, if untreated | | Symptomatic hypotension (MUSE) | ~3% | No direct permanent effect | | Penile pain | 37% (injection) | No | | Urethral burning (MUSE) | ~32% | Rarely permanent |

Sources: Caverject prescribing information [1], MUSE prescribing information [9], STEP-level key trials [2][10].

When to Stop Alprostadil and Seek Specialist Care

Stop alprostadil and schedule a urology appointment within two weeks if any of the following develop:

• A palpable nodule or hard spot anywhere along the penile shaft
• New penile curvature of any degree, especially with erection
• Pain at the injection site that persists beyond 24 hours
• Progressively decreasing rigidity despite the same dose
• Urinary stream that is weaker or more hesitant than before starting MUSE

Stop alprostadil and go to the emergency department the same day if:

• An erection lasts more than 4 hours
• The penis becomes cold, dusky, or painful without stimulation
• You experience fainting or near-fainting after using MUSE

The 2018 AUA guideline states: "Patients should be instructed to seek immediate medical attention for any erection lasting longer than four hours." [3] That instruction should be delivered verbally and in writing at every prescription visit, not only at initiation.